|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Third Department of Internal Medicine, Wakayama Medical University, School of Medicine, Wakayama, Japan
masakazu{at}wakayama-med.ac.jp
Abstract
BackgroundIt has been recently shown that the ß2-integrin molecule is upregulated on circulating neutrophils in chronic obstructive pulmonary disease (COPD) subjects. However, little has been reported about the expression of the cells' surface molecules in such patients and their relationship with pulmonary function. The aim of the present study was to investigate the surface expression of molecules on circulating neutrophils and to clarify their possible role in the airflow limitation of COPD.
MethodsThe surface expression of Mac-1 (CD-11b/CD-18), CXC receptor 1 and 2 (CXCR1, CXCR2) of circulating neutrophils from COPD patients and healthy subjects (HS) was measured by flow cytometry analysis. The serum levels of interleukin-8 (IL-8) were measured by ELISA.
ResultsBoth CD-11b and CXCR1 expression were significantly higher in COPD patients than in HS (CD-11b: HS = 9.7 ± 1.0, COPD = 14.2 ± 1.8, p < 0.05; CXCR1: HS = 9.6 ± 0.5, COPD = 11.9 ± 0.4, p < 0.01). Although aging was positively correlated with the CXCR1 expression (r = 0.440, p < 0.01), none of the other background factors including smoking and body mass index showed a correlation with the expression of the molecules. Although the serum IL-8 levels were higher in patients with COPD than in HS, no significant correlation between the serum IL-8 levels and the expression of any molecule was seen. The expression of CD-11b (r = -0.317) and CXCR1 (r = -0.383) showed a significant negative correlation with the severity of airflow limitation (both p < 0.05).
ConclusionThe over expression of CD-11b and CXCR1 on circulating neutrophils may be associated with the development of airflow limitation in COPD.
Key Words: chemokine receptor ß2-integrin interleukin-8 neutrophil chronic obstructive pulmonary disease
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |